Replies to post #193371 on Biotech Values

[DewDiligence]

(AGTC bearish argument)—AAVL has a lead in gene therapy directed at wet AMD for which AGTC is gearing up; AGTC will also be competing with its former partner Genzyme.

This is a lame argument, IMO. AGTC’s AMD program is essentially vaporware, as far as I can tell; I doubt it will ever enter clinical trials. In other words, if anyone thinks the (purported) AMD program is a material component of AGTC’s value, they’re mistaken.